GLUEMonte Rosa Therapeutics, Inc.
$10.32+63% 1Y
$10.32
$6.3352 weeks$25.31
Is it growing?
Watch
2 to watch, 1 without dataGrowth is fading: revenue shrinking (−84% year on year) and operating margin narrowing (−875.2 points).
Revenue trend−84% in a year
Trailing-twelve-month revenue vs a year earlier, from the company's own filings.
Margin direction−875.2 points operating
Trailing-twelve-month operating margin, -945.6% now against -70.4% a year earlier.
All from SEC EDGAR, as of Jun 30, 2026.
Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.
Is GLUE growing?
- Years of annual history on file
- 6
Years of annual history on file · FY2020 to FY2025, as filed
Details›
- Revenue FY2023
- $0
- Revenue FY2024
- $76M
- Revenue FY2025
- $124M
Annual income statements as filed with the SEC.
On our screens:Most shorted stocks